Cumberland Pharmaceuticals Inc.

FDA OKs Cumberland's IV ibuprofen

Federal drug regulators have approved Cumberland Pharmaceuticals' Caldolor, an intravenous version of ibuprofen that becomes the company's third portfolio drug. In their quarterly report with the SEC last month, Cumberland officials called Caldolor their "most significant product opportunity" and cited stats that put the U.S. market for injectable pain relievers at more than $300 million per year.

Jun 12, 2009 6:50 AM

Incubator teams with UT foundation

Downtown's Cumberland Emerging Technologies and the University of Tennessee Research Foundation will further explore a "promising" arthritis treatment.

"Licensing this technology is an important milestone for CET," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals and CET. "Not only are we adding a promising new product candidate to our development pipeline, we are also providing researchers with the resources necessary to advance this important work. This is precisely what we envisioned when we created CET to bridge the gap between the research laboratory and the commercial marketplace."

Feb 10, 2009 11:07 PM

Cumberland taps new product director

From Red Orbit:

Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.

Jan 13, 2009 6:17 PM

Cumberland Pharma taps product director

Jan 13, 2009 3:46 PM

Old and improved

Cumberland Pharmaceuticals says its Acetadote overdose treatment has new labels to reflect a recent study that said the drug is actually safer than was previously reported.

Dec 18, 2008 7:43 PM